i/ii

Angiotensin I II (1-6) 是由血管紧张素 I II 肽转化而来，含有 1-6 个氨基酸的多肽。血管紧张素 I 被血管紧张素转换酶水解，形成具有生物活性的血管紧张素 II。血管紧张素 II 用于高血压、特发性膜性肾病和肾素-血管紧张素系统的研究。

Angiotensin I II (1-5) 是由血管紧张素 I II 肽转化而来，有 1-5 个氨基酸组成的多肽。血管紧张素 I 是由肾素对血管紧张素原的作用形成的，血管紧张素 I 可产生血管紧张素 II 。血管紧张素 II 用于高血压、特发性膜性肾病和肾素-血管紧张素系统的研究。

Angiotensin I II (1-6) TFA is a chemical compound comprising amino acids 1-6. It is derived from the Angiotensin I II peptide, which is formed by the cleavage of the precursor angiotensinogen by renin. The resulting Angiotensin I is then hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].

Thymopoietin i/ii (29-41) (bovine) 是一种对应牛Thymopoietin II 的第29至41位的多肽段，具有神经肌肉阻滞剂的功能。

PKCβII Peptide Inhibitor I 为一种特定的PKCβII抑制剂。在大鼠心脏缺血/再灌注损伤模型中，该化合物显著表现出心脏保护效应，并能有效预防血管内皮功能障碍。

Angiotensin 1/2 (1-9) TFA(34273-12-6(free base)) 含有从血管紧张素 I/II 肽转化而来的氨基酸 1-9。

PACAP 1-38 acetate 是一种垂体腺苷酸环化酶激活多肽 (PACAP) 类似物。它与 PACAP I 型受体 (IC50 = 4 nM) 和 PACAP II 型 VIP2 受体 (IC50 = 1 nM) 结合，但不与 PACAP II 型 VIP1 受体结合。

Sar-[D-Phe8]-des-Arg9-Bradykinin acetate(126959-88-4 free base) 是一种有效的选择性缓激肽 B1 受体激动剂（兔主动脉中的 EC50 = 9.02 nM），对氨肽酶、激肽酶 I 和 II (ACE) 以及中性内肽酶切割具有抗性。在体内表现出降血压和血管生成活性。

PACAP (6-38), human, ovine, rat acetate 是一种有效的 PACAP 受体拮抗剂。PACAP (6-38) 作用于 PACAP I 型受体，PACAP II 型受体 VIP1 和 PACAP II 型受体 VIP2，IC50 分别为 30 nM，600 nM 和 40 nM。

Angiotensin I (human, mouse, rat) 是血管紧张素Ⅱ的前体物质，在血管紧张素转化酶 (ACE) 的参与下裂解成血管紧张素Ⅱ。

Suc-Ala-Ala-Pro-Phe-SBzl 是一种化合物，可以作为大鼠小肠肥大细胞蛋白酶（RMCP I）、大鼠骨骼肌肥大细胞蛋白酶（RMCP II）和胰凝乳蛋白酶（Chymotrypsin）的底物。此外，Suc-Ala-Ala-Pro-Phe-SBzl 能够被甘氨酸（R208G）水解。

Saralasin ([Sar1,Ala8] Angiotensin II) TFA，血管紧张素 II (angiotensin II) 的八肽衍生物，作为竞争性血管紧张素 II 受体 (angiotensin II receptor) 拮抗剂，其Ki值达0.32 nM（涵盖74%的结合位点），显示出部分激动剂特性。适应于肾血管性高血压、肾素依赖性（血管紧张素原性）高血压的研究。

HCVCore Protein (107-114) 是主要线性 HCV 核心区域中免疫原性极低的残基。HCVCore Protein (107-114) 被鉴定为 101-118 区域内的结合位点，其包含基因型 Ⅰ/Ⅱ 和基因型 Ⅲ/Ⅵ 之间不同的两个残基。HCVCore Protein (107-114) 可能是传播 HCV 血清型的潜在位点。

The human type I hair keratin subfamily comprises nine individual members, which can be subdivided into three groups. Group A (hHa1, hHa3-I, hHa3-II, hHa4) and B (hHa7, hHa8) each contains structurally related hair keratins, whereas group C members hHa2,

PACAP (6-38), human, ovine, rat TFA is a potent PACAP receptor antagonist with IC50 values of 30 nM, 600 nM, and 40 nM for the PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2, respectively.

Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004). Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2 References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004).

GAD65 (206-220) is a synthetic peptide derived from glutamic acid decarboxylase (GAD) 65, specifically corresponding to residues 180-188. It is known that GAD65 interacts with I-Ag7 MHC class II molecules and is a significant pancreatic antigen that self-reactive T cells target in type I diabetes mellitus.

N,S-Bis-Fmoc-Glutathione为一有效glyoxalase II抑制剂，其Ki值达0.32 mM。

AC3-I, myristoylated 为一种具有高度特异性的 CaMKII 抑制剂，为 Autocamtide-3 衍生的生物活性肽。通过将 Autocamtide-3 中的 Thr-9 磷酸化位点替换为 Ala，赋予该肽抗蛋白水解能力，从而制备出该肉豆蔻酰化形式。

Potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.

InsB (9-23) is an insulin B-chain peptide that binds to a class II histocompatibility complex (MHC) allele called I-Ag7.

Selective calpain inhibitor. Strongly inhibits calpain I (Ki = 0.2 nM) and II but does not inhibit papain, trypsin and cathepsin L (Ki = 6 μM). Increases secretion of amyoid β-protein (Aβ) 42, Aβ40 and Aβ42 ratio.

LH-RH (7-10)，一种由性腺激素释放激素 (LHRH) 在垂体和下丘脑降解过程中形成的主要四肽降解产物之一，存在于巨噬细胞、I 型样及II 型肺细胞中。

Buforin II，来源于 buforin I，从亚洲蟾蜍 Bufo bufo gargarizans 胃中分离得到的蛋白，是一种高效的抗菌 (antimicrobial) 肽。Buforin II 对广谱的革兰氏阳性和革兰氏阴性细菌具有抗菌活性。

CFP10 (71–85) 是具生物活性的肽类，能激活表达不同MHC II类与I类分子的人类CD4+和CD8+ T细胞，诱导IFN-γ产生及CTL活性。(CFP10 71–85).

Angiotensin 1 2 (1-9) 含有从血管紧张素 I II 肽转化而来的氨基酸 1-9。

Angiotensin II human (Angiotensin II) TFA 作为肾素/血管紧张素系统中关键的生物活性肽，扮演着血管收缩剂的角色并在调节人体血压中发挥中心作用。其主要通过与 G 蛋白偶联受体 (GPCRs)、血管紧张素 II 1型受体 (AT1R) 和血管紧张素 II 2型受体 (AT2R) 的相互作用来介导效应，包括刺激交感神经系统、增加醛固酮的生物合成和肾脏功能。此外，Angiotensin II human TFA 促进血管平滑肌细胞的生长和 I 型及 III 型胶原在成纤维细胞中的合成，导致血管壁与心肌增厚及纤维化，并诱导细胞凋亡。还通过LOX-1依赖的氧化还原敏感路径诱导内皮细胞中的毛细血管形成。

Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011). Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4 References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011).

PACAP (1-38), human, ovine, rat (Pituitary Adenylate Cyclase Activating Polypeptide 38) 是含有 38 个氨基酸残基的神经肽。它能够结合 PACAP I 型受体(IC50:4 nM)、PACAP II 型受体 VIP1(IC50:2 nM)、PACAP II 型受体 VIP2(IC50:1 nM)。

PEPvIII, a peptide sequence from EGFRvIII, was designed to represent a target of glioma and is presented by MHC I/II complexes.